Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 4.49 times its current sales, is high.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.86%238 617
ROCHE HOLDING LTD.8.57%233 930
ROCHE HOLDING10.11%233 930
MERCK AND COMPANY5.95%208 546
NOVARTIS18.14%206 941
NOVO NORDISK AS6.53%117 012
AMGEN-10.14%108 569
SANOFI-2.47%105 687
ABBVIE-23.78%105 319
ASTRAZENECA7.80%105 090
GLAXOSMITHKLINE9.88%101 378
ELI LILLY AND COMPANY-6.42%101 126
BRISTOL-MYERS SQUIBB COMPAN..-14.83%72 839
CELGENE CORPORATION43.44%65 173
BAYER AG-3.19%62 226
More Results
Financials (USD)
Sales 2019 81 195 M
EBIT 2019 25 495 M
Net income 2019 18 770 M
Debt 2019 7 452 M
Yield 2019 2,79%
P/E ratio 2019 19,6x
P/E ratio 2020 17,7x
EV / Sales2019 4,50x
EV / Sales2020 4,13x
Capitalization 358 B
Upcoming event on JOHNSON & JOHNSON
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes